Picture a woman of 45, a mother of two, diagnosed with breast cancer. The genetic analysis comes back HER2-positive.
→ In 1995, that result carried the worst outlook of any breast cancer
→ By 2005, trastuzumab had moved into early-stage treatment and roughly halved the risk of the cancer returning
→ By 2015, the CLEOPATRA regimen had added more than a year of survival in metastatic disease
→ By 2025, antibody-drug conjugates and targeted therapies could control brain metastases
For a woman like her, a diagnosis once measured in months can now leave years of watching her children grow up.